Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions

This article was originally published in PharmAsia News

Executive Summary

As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma

You may also be interested in...



India-Style Patent Laws Targeted In Trans-Pacific Trade Negotiations

Draft intellectual property chapter of the Trans-Pacific Partnership includes a provision prohibiting signatories from denying patents solely because a product did not show enhanced efficacy over a known product.

Biologics Exclusivity Flares Up At TTP Talks In Singapore

The Singapore round of talks to build a Trans-Pacific Partnership trade deal among 11 nations concludes in Singapore with the issue of data exclusivity for innovator biologics still in limbo.

U.S. Law On 12-Year Biologics Data Exclusivity Remains Stumbling Block To Trans-Pacific Partnership Agreement

Trans-Pacific Partnership proving to be a test case for Affordable Healthcare Act’s 12-year data exclusivity provision for biologics.

Related Content

UsernamePublicRestriction

Register

WI964848

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel